Drug Profile
Condoliase - Seikagaku Corporation
Alternative Names: C-ABC; ChABC; Chondroitin-sulfate-ABC endolyase; Chondroitinase ABC; HERNICORE; SI-6603Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Seikagaku Corporation
- Developer Kaken Pharmaceutical; Seikagaku Corporation
- Class Chondroitin lyases
- Mechanism of Action Chondroitin sulfate proteoglycan modulators; Glycosaminoglycan modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Intervertebral disc displacement
Most Recent Events
- 08 Apr 2024 Efficacy and adverse events data from phase-III Discovery 6603 trial in Intervertebral disc displacement released by Ferring Pharmaceuticals
- 26 May 2023 Seikagaku announces intention to submit BLA to the US FDA for Intervertebral disc displacement
- 26 May 2023 Efficacy and adverse event data from a phase III trial in Intervertebral disc displacement released by Ferring Pharmaceuticals